Healthcare Industry News: ProCellEx
News Release - August 27, 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCDFirst patient treated in trial of prGCD treatment of Gaucher Disease
CARMIEL, Israel, Aug. 27 (HSMN NewsFeed) -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans.
Dr. David Aviezer, President and CEO of Protalix, stated, "Enrolling our first patients in this phase III clinical trial represents a significant milestone as we work toward our goal of commercializing prGCD, our proprietary treatment for Gaucher disease. After extensive research from the committed members of our team, we believe that we have developed a treatment that will not only be effective, but also safe and cost efficient when compared to current treatment options. We look forward to monitoring the progress of our trial and the potential benefits for our participating patients."
Professor Ari Zimran added, "With the treatment of the first patient in the phase III clinical trial, we are one step closer to providing another treatment option for those who suffer from Gaucher disease. Progress to date has been very encouraging, and we expect to continue to see the benefits and advantages of prGCD in this phase III clinical trial."
About Protalix BioTherapeutics, Inc.
Protalix is a clinical stage biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix has reached an agreement with the United States Food and Drug Administration, through its Special Protocol Assessment (SPA) process, on the final design of the pivotal phase III clinical trial in the United States of Protalix's lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a lysosomal storage disorder in humans. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.
For additional information, contact Protalix BioTherapeutics at: email@example.com
Source: Protalix BioTherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.